Table I.

Expression of ADAM17 in glioma tissue and control brain tissue cases.

Group	Negative	Weakly-positive	Moderately-positive	Strongly-positive	Total
Control, n	5	2	1	0	8
Glioma (I–II), n	2	9	13	1	25
Glioma (III–IV), n	1	3	13	18	35

The overall level of ADAM17 expression was significantly higher in the WHO grade III–IV glioma tissues compared with the WHO I–II glioma and normal brain tissues, as analyzed by immunohistochemistry (P<0.05). ADAM17, a disintegrin and metalloproteinase-17; WHO, World Health Organization.